Sands Capital Life Sciences Pulse Fund II, L.P.

Sands Capital Life Sciences Pulse Fund II, L.P., 10% Owner, has filed 1 SEC report (2025), all concentrated in Inhibikase Therapeutics, Inc. (IKT), totaling $3.0M in disclosed volume. Weighing $3.0M bought versus $0 sold, the history is heavily weighted toward buying. The largest single open-market purchase on record is $3.0M in Inhibikase Therapeutics, Inc.. Data is sourced from official SEC Form 3, 4, and 5 filings.